Qianqian Guo

Qianqian Guo


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2014 in Oncology Reports
Verified
Journal Article
Open access
PDF file
MWMin-Cong Wang
Min-Cong Wang
XLXuan Liang
Xuan Liang
ZLZhi-Yan Liu
Zhi-Yan Liu
JCJie Cui
Jie Cui
YLYing Liu
Ying Liu
YYYu Yao
Yu Yao
The concurrent administration of chemotherapy and epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs) has previously produced a negative interaction and failed to confer a survival benefit to non‑small cell lung cancer (NSCLC) patients compared with first‑line cytotoxic chemotherapy. The present study aimed to investigate the optimal schedule of the combined treatment of cisplatin/paclitaxel and icotinib in NSCLC cell lines and clarify the underlying mechanisms. HCC827, H1975, H1299 and A549 human NSCLC cell lines with wild‑type and mutant EGFR genes were used as in vitro models to define the differential effects of various schedules of cisplatin/paclitaxel with icotinib treatments on cell growth, proliferation, cell cycle distribution, apoptosis, and EGFR signaling pathway. Sequence‑dependent antiproliferative effects differed among the four NSCLC cell lines, and were not associated with EGFR mutation, constitutive expression levels of EGFR or downstream signaling molecules. The antiproliferative effect of cisplatin plus paclitaxel followed by icotinib was superior to that of cisplatin or paclitaxel followed by icotinib in the HCC827, H1975, H1299 and A549 cell lines, and induced more cell apoptosis and G0/G1 phase arrest. Cisplatin and paclitaxel significantly increased the expression of EGFR phosphorylation in the HCC827 cell line. However, only paclitaxel increased the expression of EGFR phosphorylation in the H1975 cell line. Cisplatin/paclitaxel followed by icotinib influenced the expression of p‑EGFR and p‑AKT, although the expression of p‑ERK1/2 remained unchanged. The results suggest that the optimal schedule of the combined treatment of cisplatin/paclitaxel and icotinib differed among the NSCLC cell lines. The results also provide molecular evidence to support clinical treatment strategies for NSCLC patients.

1 May 2014
Verified
Journal Article
Closed access
QGQianqian Guo
Qianqian Guo
ZLZhiyan Liu
Zhiyan Liu
LJLili Jiang
Lili Jiang
THTinghua Hu
Tinghua Hu
DLDongFan Li
DongFan Li
KNKejun Nan
Kejun Nan

1 February 2014
Verified
Journal Article
Closed access
THTinghua Hu
Tinghua Hu
YYYu Yao
Yu Yao
SYShuo Yu
Shuo Yu
HGHui Guo
Hui Guo
TTTao Tian
Tao Tian
SWShuhong Wang
Shuhong Wang

21 July 2023 in Medicine
Verified
Journal Article
Open access
HZHuixian Zhang
Huixian Zhang
XLXingya Li
Xingya Li
ZZZiheng Mm Zhang
Ziheng Mm Zhang
SHSiyuan Huang
Siyuan Huang
QGQianqian Guo
Qianqian Guo
NYning yan
ning yan
As a second-generation selective oral anaplastic lymphoma kinase inhibitor, ceritinib is an effective first-line treatment for c-ros oncogene 1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC). Its efficacy and safety for the treatment of crizotinib-resistant ROS1-rearranged NSCLC were explored in the study. A retrospective single-center study was conducted to investigate the efficacy of ceritinib in crizotinib-resistant ROS1-rearranged NSCLC. The objective response rate was the primary objective, while the disease control rate, progression-free survival and adverse events were secondary objectives. From December 2015 to October 2021, a total of 246 patients with ROS1-rearranged NSCLC were screened, 12 (4.9%) of whom were treated with ceritinib after the development of crizotinib resistance. Among the 12 crizotinib-resistant patients included, 3 displayed the efficacy of partial response and 3 had the efficacy of stable condition. The objective response rate, disease control rate and median progression-free survival of all patients were 25% (95% confidence interval [CI]: −3.7% to 53.7%; 3 of 12 patients), 50% (95% CI: 16.8% to 83.2%; 6 of 12 patients), and 10.5 months (95% CI, 5.7 to 15.3 months), respectively. In addition, of the 6 patients with brain metastases, an intracranial disease control rate of 66.7% (95% CI:12.5% to 120.9%) was obtained. The research results reveal that ceritinib can be a treatment option for ROS1-rearranged NSCLC patients after the development of crizotinib resistance.

17 May 2022 in Research Square
Verified
Preprint
Open access
PDF file
KMKe Ma
Ke Ma
YLYanxin Li
Yanxin Li
XZXianwei Zhang
Xianwei Zhang
QGQianqian Guo
Qianqian Guo
Purpose: Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) played an important role in inflammatory reactions. Recently the roles of TREM-1 in cancer had been explored, but not in Glioblastoma multiforme (GBM). The study was performed to explore the significance of TREM-1 in GBM. Methods: Immunohistochemical staining of TREM-1 was performed in 91 operative patients diagnosed with GBM. Clinicopathological characteristics and survival time were recorded. Besides, TREM-1 expression and its effect on prognosis were analyzed using online GEPIA, TCGA and CGGA databases. Then the expressionprofile of TCGA-GBM cohort was used to perform functional enrichment analysis. CIBERSORT method and TIMER database were used to estimate the tumor-infiltrating immune cells (TIICs). ESTIMATE algorithm was used to estimate the immune-stromal score. Lastly, the relationships between TREM-1 and TIICs, immune-stromal score and immune checkpoint genes (ICGs) were analyzed. Results: The expression of TREM-1 was up-regulated in GBM and high TREM-1 expression predicted poor prognosis. TREM-1, IDH1, surgical resection, postoperative radiotherapy and temozolomide chemotherapy were associated with the survival time of GBM patients, but only surgical resection and TREM-1 expression were independent prognostic factors. GBM with high TREM-1 expression exhibited more infiltrate of neutrophils and macrophage. TREM-1 was positively associated with immune-stromal score and multiple ICGs, most of whom were involved in immunosuppressive responses. Conclusions: The study revealed high expression of TREM-1in GBM was an independent poor prognosis factor and TREM-1 was associated with the immunosuppressive microenvironment. Blocking TREM-1, or combing block TREM-1 and ICGs may be a strategy for enhancing GBM immune response.

9 June 2026 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
QGQianqian Guo
Qianqian Guo
LLLianghui Liang Li
Lianghui Liang Li
Narasimha M. BeerakaNarasimha M. Beeraka
Narasimha M. Beeraka
YZYi Zhang
Yi Zhang
RXRuixiang Xu
Ruixiang Xu
JLJunQi Liu
JunQi Liu